🧬Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide. 🔬Our clinical trial is now open!
Cambridge, MA
Joined March 2023
- Tweets205
- Following135
- Followers41
- Likes474
High-risk myeloma needs new approaches. K36 is speaking at #iwHRMM, Oct 21–23 in Charleston, SC.
KTX-1001, our investigational oral NSD2/MMSET inhibitor, is in Phase 1 for relapsed/refractory myeloma. Let’s connect!
K36 Therapeutics retweeted
Blood Cancer Awareness Month is a wrap! Thank you for sharing your myeloma stories online to raise awareness. This disease is now more well known, thanks to you. ❤️
#KnowMyeloma
Take-Home Message and Summary of #IMS2026 by CME Congresses via #soundcloud soundcloud.com/cme-congresse…
K36 Therapeutics retweeted
🚨𝗜𝗔𝗖𝗛 𝗡𝗲𝘄𝘀 𝗟𝗶𝘃𝗲 𝗳𝗿𝗼𝗺 #IMS2026
𝗧𝗮𝗸𝗲-𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲 𝗮𝗻𝗱 𝗦𝘂𝗺𝗺𝗮𝗿𝘆 𝗼𝗳 𝗜𝗠𝗦 𝟮𝟬𝟮𝟲
iach.org/iach-news-podcasts/
@Mohty_EBMT
Thank you @TheIACH News covering #IMS2026 summary. #NSD2/#MMSET biology in #t414 myeloma highlighting new therapeutic targets. At K36, we’re studying gintemetostat (KTX-1001), an investigational NSD2/MMSET inhibitor. #MultipleMyeloma #ClinicalTrials
What’s one thing you learned about prostate cancer this September?
Share it below. Your answer might help someone else know what to ask their healthcare team.
#ProstateCancerAwarenessMonth
Congratulations to #K36-MMSET-001 investigators Dr. @SagarLonialMD, recipient of the Waldenström Lifetime Achievement Award, and Dr. @NBahlis, recipient of the Ken Anderson Basic and Translational Research Award at #IMS2026! We’re grateful to work with you and your amazing teams.
K36 Therapeutics retweeted
How can we get more patients, no matter where they are in their myeloma journey, to experience deep, lasting treatment responses? Takeaways from #IMS2026 themmrf.org/mmrf-blogs/ims-2…
At #IMS2026 in Scotland @K36’s Myeloma Medical Director, Andrea Viqueira, and Debbie Johnson, SVP of Clinical Development Operations are meeting with investigators about a pressing question: What more can we do for people with high-risk myeloma?
Our #K36-MMSET-001 trial is studying gintemetostat (KTX-1001), an investigational NSD2/MMSET inhibitor, with a focus on t(4;14) myeloma.
Learn about the trial: clinicaltrials.gov/study/NCT…
Cancer research moves forward because patients, trial participants, clinicians, and scientists keep asking what could be better.
On #WorldCancerResearchDay, we’re grateful for everyone helping turn those questions into progress. At K36, we’re studying #NSD2 in myeloma and prostate cancer.
K36 Therapeutics retweeted
Today is KnowMyeloma Day. On the last Thursday of Blood Cancer Awareness Month, we shine a spotlight on myeloma. Tell us: What does knowing myeloma mean to you?
#KnowMyeloma #BloodCancerAwarenessMonth
K36 Therapeutics retweeted
Today is KnowMyeloma Day. Every day, thousands of families face multiple myeloma and other blood cancers. Earlier detection, better treatments, and stronger support start with awareness.
#KnowMyeloma #BloodCancerAwarenessMonth
K36 Therapeutics is heading to Glasgow for #IMS2026! We look forward to connecting with myeloma investigators, care teams, patients, and advocates to discuss KTX-1001 (gintemetostat) and our MMSET clinical trial.
Meet with us: [email protected]
K36 Therapeutics retweeted
Mark your calendars! Dr. Douglas Sborov joins the IMF live on Tues., Sept. 29 at 4pm PT/7pm ET for a #KnowMyeloma Q&A on treatment advances & navigating myeloma. Bring your questions! Click "Going" on Facebook and turn on notifications to RSVP: facebook.com/events/13887781…
Thank you to #Philadelphia #myeloma advocate @RichardArmstrong for sharing his journey and urging others to recognize symptoms and seek a hematology specialist at #pennmedicine
📍Bushwick, Brooklyn
#KnowMyeloma #MultipleMyeloma
K36 Therapeutics retweeted
Delays in diagnosis. Fewer specialist referrals. Less access to clinical trials. These are the realities many Black myeloma patients face. Learn how IMF combats health disparities at mpower.myeloma.org
#KnowMyeloma #IMFMPOWER
K36 Therapeutics retweeted
ASH officers were on Capitol Hill advocating for the future of medical research, urging lawmakers to rescind the proposed OMB grantmaking rule & provide the highest possible NIH funding level in FY27.
Learn more: ow.ly/1b1v50ZOwaj
#Fight4Hematology
K36 Therapeutics retweeted
What Does FISH Testing Reveal About Multiple #Myeloma Risk and Treatment? #mmsm
youtu.be/9TIyXj3H5qM
K36 Therapeutics retweeted
🚨New episode out now!🚨
Hip, Hope, Hooray! Black Men Talking Health healthhopehiphop.org/hip-hop…
Doubt, Disbelief & Delayed Diagnosis: Multiple Myeloma ain’t no joke, Black folks!
In this episode, four men (three black and one white) come together to discuss the challenges they faced with delayed diagnosis of multiple myeloma and the impact it had on their treatment. They delve into the disparities in healthcare access and quality that often impact the black community, leading to -- you guessed it -- delayed diagnoses and poorer outcomes for black patients with multiple myeloma.
#hiphopehooray #myeloma #healthhopehiphop #blackhealth #bloodcancer